Principia Biopharma Inc Revenue Growth Rates (PRNB), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Principia Biopharma Inc   (NASDAQ: PRNB)
 

PRNB's Revenue Growth by Quarter and Year

Principia Biopharma Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

PRNB Revenue (in millions $) FY 2020 FY 2019 FY 2018 FY 2017
4th Quarter December -
3rd Quarter September -
2nd Quarter June 50.00
1st Quarter March 0.00
FY 50.00





PRNB Revenue second quarter 2020 Y/Y Growth Comment
Principia Biopharma Inc showed record Revenue increase in the second quarter 2020 with 66.67% from the second quarter 2020 2019, to $ 50.00 millions.

Looking into second quarter 2020 results within Major Pharmaceutical Preparations industry 45 other companies have achieved higher Revenue growth. While Principia Biopharma Inc ' s Revenue jump of 66.67% ranks overall at the positon no. 277 in the second quarter 2020.


PRNB Revenue ( Y/Y Growth %) 2020
 2019 2018 2017
4th Quarter December - - 673.37 % -
3rd Quarter September - - 1129.14 % -
2nd Quarter June 66.67 % 130.95 % 3508.33 % -
1st Quarter March - -54.93 % - -
FY   - -49.15 % 1216.95 % -

Financial Statements
Principia Biopharma Inc 's second quarter 2020 Revenue $ 50.00 millions PRNB's Income Statement
Principia Biopharma Inc 's second quarter 2019 Revenue $ 30.00 millions Quarterly PRNB's Income Statement


PRNB Revenue (Quarter on Quarter Growth %)

 2020
 2019 2018 2017
4th Quarter December - - 40.84 % 123.84 %
3rd Quarter September - - 42.88 % 319.44 %
2nd Quarter June - 481.4 % 13.45 % -
1st Quarter March - -80.26 % 238.76 % -
FY (Year on Year)   - -49.15 % 1216.95 % -


Back to PRNB Growth rate Comparisons >> Back to PRNB Growth rate Comparisons >>


Revenue second quarter 2020 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #46
Healthcare Sector #83
Overall #277

Revenue Y/Y Growth Statistics
High Average Low
66.67 % -44.44 % -100 %
(Jun 30 2020)   (Mar 31 2020)
Revenue second quarter 2020 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #46
Healthcare Sector #83
Overall #277
Revenue Y/Y Growth Statistics
High Average Low
66.67 % -44.44 % -100 %
(Jun 30 2020)   (Mar 31 2020)

Revenue by Quarter for the Fiscal Years 2017, 2018, 2019, 2020

Principia Biopharma Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


PRNB's II. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


PRNB's II. Quarter Q/Q Revenue Comment


Principia Biopharma Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2020)		 12 Months Ending
(Mar 31 2020)		 12 Months Ending
(Dec 31 2019)		 12 Months Ending
(Sep 30 2019)		 12 Months Ending
(Jun 30 2019)
Cumulative Revenue 12 Months Ending $ 0.00 $ 0.00 $ 0.00 $ 0.00 $ 79.86
Y / Y Revenue Growth (TTM) - - - - 172.35 %
Year on Year Revenue Growth Overall Ranking # # # # # 145
Seqeuential Revenue Change (TTM) - - - - 27.07 %
Seq. Revenue Growth (TTM) Overall Ranking # # # # # 145


Cumulative Revenue growth Comment
Principia Biopharma Inc realized trailing twelve months of $ 0 millions, in the Jun 30 2020, compare to Revenue of $ 80 millions a year ago.

In the Healthcare sector 38 other companies have achieved higher trailing twelve month Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 26
Healthcare Sector # 39
Overall # 119

Revenue TTM Y/Y Growth Statistics
High Average Low
276.4 %
 224.38 %
172.35 %
(Mar 31 2019)  


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 80
Sector # 175
S&P 500 # 612
Cumulative Revenue growth Comment
Principia Biopharma Inc realized trailing twelve months of $ 0 millions, in the Jun 30 2020, compare to Revenue of $ 80 millions a year ago.

In the Healthcare sector 38 other companies have achieved higher trailing twelve month Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 26
Healthcare Sector # 39
Overall # 119

Revenue TTM Y/Y Growth Statistics
High Average Low
276.4 %
224.38 %
172.35 %
(Mar 31 2019)  


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 80
Sector # 175
S&P 500 # 612




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
PRNB's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Jun 30 2020 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2020
Palvella Therapeutics Inc 110.92%$ 110.915 millions
Viemed Healthcare Inc 110.84%$ 110.844 millions
Regenxbio Inc 110.20%$ 110.202 millions
Geovax Labs Inc 109.87%$ 109.869 millions
Nektar Therapeutics109.51%$ 109.509 millions
Fulgent Genetics Inc 104.95%$ 104.950 millions
Atyr Pharma Inc 101.06%$ 101.064 millions
Biocryst Pharmaceuticals Inc 98.27%$ 98.273 millions
Kadmon holdings inc 98.23%$ 98.230 millions
Aquestive Therapeutics Inc 94.76%$ 94.761 millions
Blueprint Medicines Corporation94.31%$ 94.305 millions
Fate Therapeutics Inc 94.00%$ 94.001 millions
Macrogenics Inc 91.23%$ 91.230 millions
Lifeward ltd 90.19%$ 90.194 millions
Astrotech Corp88.51%$ 88.506 millions
Zynex inc 87.07%$ 87.074 millions
Adapthealth Corp 86.96%$ 86.958 millions
Quidelortho Corp86.37%$ 86.374 millions
Jaguar Health Inc 85.67%$ 85.672 millions
Teladoc Health Inc 85.01%$ 85.015 millions
Cytomx Therapeutics Inc 84.27%$ 84.267 millions
American Bio Medica Corporation83.51%$ 83.507 millions
Athenex Inc 80.98%$ 80.979 millions
Reflect Scientific Inc76.72%$ 76.725 millions
Therapeuticsmd Inc 76.04%$ 76.037 millions
Meridian Bioscience Inc 75.06%$ 75.056 millions
Scorpius Holdings inc 73.19%$ 73.193 millions
Agenus Inc71.46%$ 71.460 millions
Polarityte Inc 70.89%$ 70.890 millions
Gw Pharmaceuticals Plc68.38%$ 68.379 millions


About Principia Biopharma Inc Revenue Growth Rates (PRNB), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.